GLUE
Monte Rosa Therapeutics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
14.35
▼ 0.43 (2.91%)
MARKET · —
Price
Open
14.78
Prev close
14.78
Day high
15.00
Day low
14.17
Volume
945.61K
Market cap
$1.22B
P/E (TTM)
—
52W range
4.54 – 25.77
Trailing performance
Returnvs SPY
1W
-7.74%
-6.4%
1M
-37.91%
-41.6%
3M
-24.26%
-27.4%
6M
-24.66%
-35.7%
YTD
-8.80%
-21.1%
1Y
+222.80%
+202.8%
3Y
+121.02%
+46.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$1.22B
Enterprise value$636.86M
Revenue (TTM)$28.73M
Gross profit$-133.63M
EBITDA$-173.73M
Net income$-161.12M
EPS (TTM)$-1.75
Free cash flow$-74.45M
Total cash$621.10M
Total debt$37.99M
Book value / share$5.72
Shares outstanding85.31M
Float54.48M
Short % of float19.59%
Dividend yield—
Beta (5Y)1.53
Valuation & profitability ratios
Trailing P/E—
Forward P/E-7.62
PEG ratio—
Price / sales—
Price / book2.50
EV / revenue22.17
EV / EBITDA-3.67
Gross margin0.00%
Operating margin-547.84%
Profit margin0.00%
Return on equity-42.66%
Return on assets-21.63%
Debt / equity7.80
Current ratio10.58
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $123.67M | $75.62M | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$38.63M | -$72.70M | -$135.35M | -$108.50M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$38.63M | -$72.70M | -$135.35M | -$108.50M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.37 | -0.43 | -17.6% |
| Mar 2026 | -0.38 | -0.45 | -19.1% |
| Dec 2025 | -0.34 | -0.55 | -63.4% |
| Sep 2025 | -0.35 | -0.33 | +6.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.35 | 7 | $18.92M | +48.2% |
| Next quarter | -0.37 | 7 | $21.63M | +677.9% |
| Current year | -1.57 | 7 | $53.67M | -56.6% |
| Next year | -1.88 | 7 | $57.07M | +6.3% |
Analyst targets & ownership
Mean target$28.50
High target$37.00
Low target$25.00
Implied upside98.61%
Analyst count6
ConsensusSTRONG BUY
Strong buy / Buy2 / 6
Hold0
Sell / Strong sell0 / 0
Held by insiders0.56%
Held by institutions115.73%
Institutions holding258
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
-50.62K
Net selling
Buy transactions
16
128.46K shares
Sell transactions
23
179.08K shares
Net transactions
+39
Buys less sells
Sell : buy shares
1.4 : 1
Mixed
Insider-held shares
478.61K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 16, 26 | WARMUTH MARKUS M.D. Chief Executive Officer |
SELL | 9.50K | $220.22K | Direct |
| Jul 15, 26 | CHAMPOUX JENNIFER Chief Operating Officer |
CONVERSION | 4.35K | $17.32K | Direct |
| Jul 15, 26 | CHAMPOUX JENNIFER Chief Operating Officer |
SELL | 4.35K | $101.73K | Direct |
| Jul 6, 26 | TOWNSON SHARON Officer |
CONVERSION | 6.00K | $36.84K | Direct |
| Jul 6, 26 | TOWNSON SHARON Officer |
SELL | 6.00K | $139.85K | Direct |
| Jun 30, 26 | JANKU FILIP Officer |
CONVERSION | 5.41K | $72.51K | Direct |
| Jun 30, 26 | JANKU FILIP Officer |
SELL | 5.41K | $132.47K | Direct |
| Jun 29, 26 | MANNING ANTHONY M Director |
CONVERSION | 10.00K | $41.60K | Direct |
| Jun 29, 26 | JANKU FILIP Officer |
CONVERSION | 6.00K | $45.36K | Direct |
| Jun 29, 26 | JANKU FILIP Officer |
SELL | 6.00K | $137.70K | Direct |
| Jun 29, 26 | MANNING ANTHONY M Director |
SELL | 10.00K | $231.10K | Direct |
| Jun 24, 26 | JANKU FILIP Officer |
CONVERSION | 36.00K | $272.16K | Direct |
| Jun 24, 26 | JANKU FILIP Officer |
SELL | 41.84K | $882.20K | Direct |
| Jun 23, 26 | TOWNSON SHARON Officer |
CONVERSION | 3.00K | $18.42K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BOWEN MATTHEW |
Officer | 25.90K | Stock Award(Grant) |
CHAMPOUX JENNIFER |
Chief Operating Officer | 62.37K | Conversion of Exercise of derivative security |
DUNN EDMUND |
Officer | 22.55K | Sale |
JANKU FILIP |
Officer | 60.61K | Conversion of Exercise of derivative security |
LEO CHANDRA P. MD |
Director | 10.00K | Purchase |
MANNING ANTHONY M |
Director | 0 | Conversion of Exercise of derivative security |
NICKSON PHILIP |
Officer | 55.00K | Sale |
TOWNSON SHARON |
Officer | 67.84K | Conversion of Exercise of derivative security |
VERSANT VENTURE CAPITAL VI, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
WARMUTH MARKUS M.D. |
Chief Executive Officer | 585.04K | Sale |
Moving averages & technicals
SMA 10
15.41
-6.90% from price
SMA 20
16.91
-15.42% from price
SMA 50
19.98
-28.44% from price
SMA 100
19.27
-25.53% from price
SMA 200
18.49
-22.65% from price
EMA 12
15.80
-9.18% from price
EMA 26
17.48
-17.89% from price
EMA 50
18.63
-22.99% from price
RSI (14)
29.6
Oversold
MACD (12,26,9)
-1.68
Hist -0.08
ATR (14)
0.77
5.36% of price
Realised vol 30D
103.2%
Annualised
Bollinger upper
22.30
20, 2σ
Bollinger lower
11.51
20, 2σ
50 / 200 cross
Golden
19.98 vs 18.49
Trend bias
Below 200
-22.65%
Risk profile
Beta vs SPY
1.00
Less volatile than market
Correlation to SPY
0.13
Largely independent
Realised vol 30D
103.2%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-43.5%
Peak to trough
Max drawdown 5Y
-94.1%
Peak to trough
ATR 14
0.77
5.36% of price
Beta (reported)
1.53
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
3.96
Put-heavy session
Put / call open interest
7.59
Positioning, not flow
Max pain
20.00
+39.9% from spot
ATM implied vol
189.5%
Nearest strike to spot
Skew (10% OTM)
-20.7%
Calls bid over puts
Call volume
24
Contracts, this expiry
Put volume
95
Contracts, this expiry
Heaviest call OI
20.00
110 contracts
Heaviest put OI
12.50
760 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Monte Rosa Therapeutics (GLUE) Is Down 30.7% After Deepening Q2 Losses And H1 Earnings Reversal
Simply Wall St. · 15d ago
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates
Zacks · 16d ago
Monte Rosa Therapeutics: Q2 Earnings Snapshot
Associated Press · 16d ago
Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
GlobeNewswire · 16d ago
BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection?
Stocktwits · 22d ago
Novo Nordisk Shares Sink After Heart Disease Drug Candidate Fails Late-Stage Trial
MT Newswires · 22d ago
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 51d ago
After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale?
Motley Fool · 54d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.